Medicines: Marketing Authorisation Holders' submission of Nitrosamine risk evaluation, risk assessment and confirmatory testing
In line with CHMP opinion on nitrosamine impurities in human medicinal products, as a precaution, marketing authorisation holders should review manufacturing processes to identify and, if found, to mitigate risk of these impurities being present.
Source:
Medicines and Healthcare products Regulatory Agency